Search the Newsreel

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues …

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

NeoGenomics (NEO) reported a return to quarterly profitability in Q2 2026 with revenue of US$201.66 million and a net income of US$2.24 million, a significant improvement from a net loss the previous year. Management also narrowed its expected full-year 2026 net loss and slightly …

ServiceNow Inc Stock (NOW) Moved Up by 6.27% on Aug 7: Key Drivers Unveiled

ServiceNow Inc. (NOW) stock surged by 6.27% on August 7, driven by strong quarterly financial results that surpassed expectations, primarily due to the successful monetization of its generative AI capabilities and increased contract values. Wall Street analysts have raised price targets for NOW, citing …

Amphenol approves two-for-one stock split, updates Q3 adjusted EPS and declares Q3 dividend

Amphenol (APH) has announced a two-for-one stock split via a stock dividend, payable on September 2, 2026, with a record date of August 17, 2026. The company also updated its Q3 2026 adjusted diluted EPS guidance to $0.70–$0.71 post-split and declared a Q3 2026 …

Bionano Genomics Inc (BNGO) Stock News Today

This article provides current stock information for Bionano Genomics Inc (BNGO), showing a recent increase of 5.45%. It indicates that more news regarding BNGO's stock, earnings, and analyst ratings will be available soon. The page serves as a hub for financial data and updates …

Enovis Corporation Stock 12‑Month Price Target Cut to $41.25, Implies 37% Upside

The average 12-month price target for Enovis Corporation (ENOV) stock has been lowered from $41.58 to $41.25 by analysts, despite this reduction, the new target still suggests a potential upside of approximately 37% based on the August 5th closing price. The consensus rating for …

Metagenomi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Metagenomi Therapeutics Inc is projected to report a loss of 57 cents per share. This earnings preview from Refinitiv indicates the company's expected financial performance. The full article is available on TradingView, offering unlimited access to news from various sources.

BNGO Q2'26 Earnings: EPS estimate is (0.67) USD

Bionano Genomics, Inc. (BNGO) is scheduled to release its Q2'26 financial results on August 10, after market close. The company is expected to report an estimated revenue of $7.55 million and an estimated earnings per share (EPS) of ($0.67) for the quarter. This article …

Terreno Realty Corporation (NYSE:TRNO) to Issue Dividend Increase - $0.57 Per Share

Terreno Realty Corporation (NYSE:TRNO) announced a quarterly dividend increase to $0.57 per share, payable on October 9th to shareholders of record on September 30th. This represents a 9.6% increase from its previous dividend and an annualized yield of 3.3%. While the current payout ratio …

Cenovus Energy (TSE:CVE) Shares Cross Above 200-Day Moving Average - Time to Sell?

Cenovus Energy (TSE:CVE) shares recently crossed above their 200-day moving average, signaling improved technical momentum. The company reported strong quarterly earnings and increased its dividend, yet insiders have sold a significant number of shares. Analysts maintain a bullish outlook with an average "Buy" rating …

Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO

Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 9.2% in the first quarter, purchasing an additional 225,588 shares, bringing its total holdings to 2.67 million shares valued at approximately $19.8 million. This acquisition reflects a broader institutional interest in NeoGenomics, …

NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co.

Sei Investments Co. significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 320.7% during the first quarter, now holding 466,199 shares valued at $3.46 million. This move is mirrored by other institutional investors, collectively owning 98.5% of the company's stock, despite a recent insider …

Enovis Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:ENOV) 2026-08-07

Xenora Minerals (ASX:XRA) Shares Rise 11% as Dudley Lithium Work Continues

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' azetukalner NDA filing remains on track following a productive pre-NDA meeting with the FDA, according to RBC. However, the full article content is only available to premium subscribers.

Menon Bearings shareholders approve FY26 results and interim dividend

How NeoGenomics’ Q2 Profit Return And Higher 2026 Outlook At NeoGenomics (NEO) Has Changed Its Investment Story

NeoGenomics (NEO) reported a return to profitability in Q2 2026 with US$2.24 million net income and raised its full-year 2026 revenue outlook to US$802 million–US$806 million, indicating improving operational performance. This positive shift strengthens the company's investment narrative, emphasizing its role as a specialized …

NeoGenomics, Inc. Revenue Breakdown – BX:NG9

NeoGenomics, Inc. (BX:NG9) generated 576.61 million CHF in revenue last year. The "Client Direct Billing" segment was the top performer, contributing 411.32 million CHF, a decrease from the previous year. The United States was the primary regional contributor, accounting for all of the company's …

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional …

Enovis earnings beat by $0.05, revenue topped estimates

Enovis Q2 2026 presentation shows margin gains, stock falls 9%

Enovis Q2 2026 slides show margin gains despite stock decline

Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The …

FMR LLC discloses 5.7% Amphenol (APH) stake held through affiliated entities

FMR LLC reported a 5.7% beneficial ownership stake in Amphenol Corporation's Class A common stock, totaling 70,486,300.18 shares as of June 30, 2026, via an Amendment No. 27 to a Schedule 13G filing. Abigail P. Johnson is also reported with the same beneficial ownership, …

Enovis reaffirms 2026 outlook and targets >25% free cash flow conversion as Arvis rollout expands

Earnings Call Insights: Enovis (ENOV) Q2 2026 MANAGEMENT VIEW * CEO Damien McDonald said Q2 results showed “the strength and stability of our diversified product portfolio” and reported “organic growth of 5%, driven by 6% organic growth in Recon and 3% organic growth in …

10x Genomics raises 2026 revenue outlook to $610M-$630M as Atera shipments remain about 40 units

Earnings Call Insights: 10x Genomics (TXG) Q2 2026 MANAGEMENT VIEW * "Revenue for the second quarter was $151 million" (CEO Serge Saxonov) and management highlighted a nonrecurring item: "we recognized $1.6 million of license and royalty revenue in connection with our settlement with Takara" …

Edding Genor Advances GB268 Breast Cancer Trial with First Patient Dosed

Cenovus Energy (TSX:CVE) Lifts Guidance Following Strong Results With Valuation Back In Focus

Cenovus Energy recently reported strong second-quarter 2026 results, showing higher sales, net income, and upstream production, alongside updated guidance and capital returns through dividends and share buybacks. Despite a significant year-to-date share price increase of 64.70% and a five-year return of 326.13%, the company …

Enovis Backs 2026 Guidance >ENOV

Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.

Xenon Reports Q2 2026 Financial Results and Provides Business Update

Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 …

10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations

10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash

10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by …

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Terreno Realty Corporation (TRNO) stock price, news, quote and history

Terreno Realty Corporation (TRNO) is an acquirer, owner, and operator of industrial real estate in six major coastal U.S. markets. The company recently executed new renewal leases totaling 233,000 square feet at Countyline Corporate Park Phase III in Hialeah, Florida. Terreno's stock closed at …

RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com

RenovoRx Inc. announced that its RenovoCath drug-delivery device was used commercially for the first time to treat a sarcoma patient at CARTI Cancer Center. This marks an expansion beyond the company's prior focus on pancreatic cancer, demonstrating the device's potential for local chemotherapy delivery …

10X GENOMICS ($TXG) Releases Q2 2026 Earnings